GlassScriptPhysician profile
Daniel Neville
NPI 1033588546
$1,358.06
in general payments reported to CMS, 2019-2025
13 companies · $526 in 2025
The $526 reported for 2025 was more than what 81% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $83.48 · 2023: $267 · 2024: $367 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $336.22 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $240.44 | 2022-2025 | Inspiris Resilia Aortic Valve, Mitris Resilia Mitral Valve |
| Abiomed | $186.07 | 2023-2025 | Impella |
| Getinge USA Sales, LLC | $130.68 | 2023-2025 | Vasoview Hemopro 2, Vasoview Hemopro 2 |
| Intuitive Surgical, INC. | $114.55 | 2021 | |
| Medical Device Business Services, INC. | $113.46 | 2024 | Surgicel Nu-Knit |
| Haemonetics Corporation | $65.29 | 2025 | Teg6s Hemostasis System |
| Ethicon US, LLC | $56.10 | 2022-2024 | Ethibond Excel, Vistaseal, Evarrest |
| Abbott Laboratories | $28.64 | 2025 | Navitor |
| Kiniksa Pharmaceuticals, LTD. | $28.00 | 2023 | Arcalyst |
| Solventum Corporation | $22.00 | 2024 | Prevena, V.A.C. Veraflo |
| Atricure, INC. | $20.19 | 2022 | |
| Innovation Technologies INC | $16.42 | 2023 | Irrisept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Neville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.